期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

心室率控制对快速房颤患者血浆BNP、CRP及心脏形态的影响 被引量：3

下载PDF
导出
摘要 目的探讨心室率控制对预防快速房颤的作用及机制。方法对98例快速房颤患者予初始剂量美托洛尔12.5mg,2次/d,逐渐加量至目标心率(75±5)次/min并维持1a,严密观察病情变化;在治疗前和治疗达到目标心率维持1a时分别用免疫比浊法测血浆脑钠肽(BNP)水平,电化学发光法测血浆C反应蛋白(CRP)浓度,用彩超机测量左室射血分数(EF)、各心腔舒张末期内径值。结果快速房颤患者心室率得到控制后,BNP明显降低、CRP明显降低(P<0.01),左、右心房及心室均明显缩小(P<0.05),EF值明显增高(P<0.05)。结论通过控制心室率能预防快速房颤患者心肌重构、心衰,明显降低参与血栓形成的CRP水平。
作者 唐文峰 孙鲁民 张守林 徐丽雅 徐长钰
机构地区 济钢集团总医院
出处 《山东医药》 CAS 北大核心 2009年第51期85-86,共2页 Shandong Medical Journal
关键词 心率 房颤 脑钠肽 C反应蛋白 心房 心室
分类号 R541.75 [医药卫生—心血管疾病]
  • 相关文献

参考文献6

  • 1朱建国,那开宪.2006年心房颤动治疗指南解读(2)——预防血栓栓塞[J].中国医刊,2007,42(3):55-58. 被引量：9
  • 2余国膺.CRP不仅是个标志,它直接参与血栓形成[J].岭南心血管病杂志,2003,9(6):456-456. 被引量：7
  • 3Zaman A G,Kearney M T,Schecter C,et al.Angiotensin-converting enzyme inhibitors as adjunctive therapy in patients with persistent atrial fibrillation. American Heart Journal . 2004 被引量：1
  • 4Kumagai K,Nakashima H,Urata H,et al.Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. Journal of the American College of Cardiology . 2003 被引量：1
  • 5Sudoh T,Kangawa K,Minamino N,et al.A new natriuretic peptide in porcine brain. Nature . 1998 被引量：1
  • 6Ohta Y,Shimada T,Yoshitomi H,et al.Drop in plasma brain natriuretic peptide levels after successful direct current cardioversion in chronic atrial fibrillation. Canadian Journal of Cardiology . 2001 被引量：1

二级参考文献9

  • 1周自强,胡大一,陈捷,张仁汉,李奎宝,赵秀丽.中国心房颤动现状的流行病学研究[J].中华内科杂志,2004,43(7):491-494. 被引量：1399
  • 2Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines ( Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation ): developed in collaboration with the Europearl Heart Rhythm Association and the Heart Rhythm Society[J]. Circulation,2006, 114 (7) :e257 - 354. 被引量：1
  • 3Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences( Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology [ J ]. Eur Heart J,2001,22 (20) : 1852 - 1923. 被引量：1
  • 4Prystowsky EN, Benson DW Jr, Fuster V, et al. Management of patients with atrial fibrillation. A Statement for Healthcare Professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association[ J ]. Circulation, 1996,93(6) :1262 - 1277. 被引量：1
  • 5Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis[J]. Ann Intern Med, 1999,131(7):492 -501. 被引量：1
  • 6Halperin JL. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and base-line patient characteristics ( SPORTIF Ⅲ and Ⅴ) [ J ]. Am Heart J,2003,146(3):431 -438. 被引量：1
  • 7Morocutti C, Amabile G, Fattapposta F, et al. Indobufen versus warfarin in the secondary prevention of major vascular events in non-rheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators[ J]. Stroke, 1997,28(5 ) : 1015 - 1021. 被引量：1
  • 8Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study [ J ]. JAMA,2001,285 ( 18 ) : 2370 -2375. 被引量：1
  • 9ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W) : a randomised controlled trial[J]. Lancet, 2006,367(9526): 1903 -1912. 被引量：1

共引文献14

同被引文献32

引证文献3

二级引证文献14

山东医药
2009年 第51期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部